A C Calkin

Summary

Affiliation: Baker Heart Research Institute
Country: Australia

Publications

  1. ncbi PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse
    Anna C Calkin
    JDRF Danielle Alberti Memorial Centre for Diabetes Complications, Baker Heart Research Institute, Melbourne, Australia
    Nephrol Dial Transplant 21:2399-405. 2006
  2. ncbi Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse
    Anna C Calkin
    Danielle Alberti Memorial Centre for Diabetic Complications, Baker Medical Research Institute, Melbourne, Australia
    Atherosclerosis 195:17-22. 2007
  3. ncbi Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention
    Anna C Calkin
    JDRF Danielle Alberti Memorial Centre for Diabetes Complications, Baker Heart Research Institute, Melbourne, Victoria, Australia
    Am J Cardiovasc Drugs 6:15-40. 2006
  4. ncbi Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation
    A C Calkin
    Diabetes Complications Laboratory, Baker Heart Research Institute, P O Box 6492, St Kilda Rd Central, Melbourne, 8008, Australia
    Diabetologia 49:766-74. 2006
  5. ncbi Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects
    Anna C Calkin
    JDRF Danielle Alberti Centre for Diabetes Complications, Vascular Division, Wynn Domain, Baker Heart Research Institute, Melbourne 8008, Australia
    Arterioscler Thromb Vasc Biol 25:1903-9. 2005
  6. ncbi MK-767. Kyorin/Banyu/Merck
    Anna C Calkin
    Danielle Alberti Memorial Centre for Diabetic Complications, Baker Medical Research Institute, St Kilda Rd Central, Melbourne, Victoria 8008, Australia
    Curr Opin Investig Drugs 4:444-8. 2003
  7. ncbi The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation
    A C Calkin
    Diabetes Complications Laboratory, Baker Heart Research Institute, P O Box 6492, St Kilda Rd Central, Melbourne 8008, Victoria, Australia
    Diabetologia 51:1731-40. 2008
  8. ncbi The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse
    Sara Giunti
    Baker IDI Heart and Diabetes Institute, Monash University, Melbourne, Australia
    Am J Physiol Renal Physiol 299:F528-35. 2010
  9. ncbi Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice
    A M D Watson
    Diabetes Division, Baker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Road Central, Melbourne, Vic, 8008, Australia
    Diabetologia 54:681-9. 2011
  10. ncbi PPARs and diabetes-associated atherosclerosis
    A C Calkin
    JDRF Centre for Diabetes Complications, Baker Heart Research Institute, Melbourne, Australia
    Curr Pharm Des 13:2736-41. 2007

Collaborators

Detail Information

Publications20

  1. ncbi PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse
    Anna C Calkin
    JDRF Danielle Alberti Memorial Centre for Diabetes Complications, Baker Heart Research Institute, Melbourne, Australia
    Nephrol Dial Transplant 21:2399-405. 2006
    ....
  2. ncbi Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse
    Anna C Calkin
    Danielle Alberti Memorial Centre for Diabetic Complications, Baker Medical Research Institute, Melbourne, Australia
    Atherosclerosis 195:17-22. 2007
    ..This study aimed to investigate the actions of the non-thiazolidinedione PPARalpha/gamma agonist, compound 3q, on plaque development in the apolipoprotein E knockout (apoE KO) mouse, a recognised model of accelerated plaque development...
  3. ncbi Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention
    Anna C Calkin
    JDRF Danielle Alberti Memorial Centre for Diabetes Complications, Baker Heart Research Institute, Melbourne, Victoria, Australia
    Am J Cardiovasc Drugs 6:15-40. 2006
    ..Furthermore, it reflects the need for combination therapy to combat this disease...
  4. ncbi Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation
    A C Calkin
    Diabetes Complications Laboratory, Baker Heart Research Institute, P O Box 6492, St Kilda Rd Central, Melbourne, 8008, Australia
    Diabetologia 49:766-74. 2006
    ..We investigated putative mechanisms responsible for these anti-atherogenic effects in an in vivo model of diabetes-associated atherosclerosis...
  5. ncbi Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects
    Anna C Calkin
    JDRF Danielle Alberti Centre for Diabetes Complications, Vascular Division, Wynn Domain, Baker Heart Research Institute, Melbourne 8008, Australia
    Arterioscler Thromb Vasc Biol 25:1903-9. 2005
    ..To assess the vascular effects of thiazolidinediones, independent of their metabolic effects, we observed the effect of rosiglitazone on diabetes-associated atherosclerosis in a model of insulin insufficiency...
  6. ncbi MK-767. Kyorin/Banyu/Merck
    Anna C Calkin
    Danielle Alberti Memorial Centre for Diabetic Complications, Baker Medical Research Institute, St Kilda Rd Central, Melbourne, Victoria 8008, Australia
    Curr Opin Investig Drugs 4:444-8. 2003
    ..The compound is currently undergoing phase III trials in the US and phase I trials in Japan...
  7. ncbi The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation
    A C Calkin
    Diabetes Complications Laboratory, Baker Heart Research Institute, P O Box 6492, St Kilda Rd Central, Melbourne 8008, Victoria, Australia
    Diabetologia 51:1731-40. 2008
    ....
  8. ncbi The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse
    Sara Giunti
    Baker IDI Heart and Diabetes Institute, Monash University, Melbourne, Australia
    Am J Physiol Renal Physiol 299:F528-35. 2010
    ..The combination treatment is not superior to monotherapies...
  9. ncbi Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice
    A M D Watson
    Diabetes Division, Baker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Road Central, Melbourne, Vic, 8008, Australia
    Diabetologia 54:681-9. 2011
    ....
  10. ncbi PPARs and diabetes-associated atherosclerosis
    A C Calkin
    JDRF Centre for Diabetes Complications, Baker Heart Research Institute, Melbourne, Australia
    Curr Pharm Des 13:2736-41. 2007
    ..The potential clinical implications of these findings are also discussed in view of the recently reported results of the PROACTIVE and FIELD clinical trials with the PPAR agonists rosiglitazone and fenofibrate respectively...
  11. ncbi Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products
    Markus Lassila
    Danielle Alberti Memorial Centre for Diabetes Complications, Vascular Division, Wynn Domain, Baker Heart Research Institute, Melbourne, Victoria, Australia
    J Am Soc Nephrol 15:2125-38. 2004
    ..The accelerated renal injury that was observed in diabetic apo E-KO mice was attenuated by approaches that inhibit renal AGE accumulation...
  12. ncbi Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-beta in a murine diabetic model of atherosclerosis
    Y Pham
    Diabetes and Metabolism Division, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia
    Diabetologia 53:170-9. 2010
    ..We explored how a recently identified molecule, cell division autoantigen 1 (CDA1), influences the profibrotic TGF-beta pathway leading to vascular ECM accumulation...
  13. ncbi Drug evaluation: K-111, an insulin-sensitizing peroxisome proliferator-activated receptor alpha agonist
    Brian G Drew
    Baker Heart Research Institute, Juvenile Diabetes Research Foundation Centre for Diabetes Complications, PO Box 6492, St Kilda Road Central, Melbourne 8008, Australia
    Curr Opin Investig Drugs 8:324-30. 2007
    ..Phase II clinical trials of K-111 are underway...
  14. ncbi Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes
    Aino Soro-Paavonen
    Albert Einstein Juvenile Diabetes Research Foundation Centre for Diabetes Complications, Diabetes Metabolism Division, Baker Heart Research Institute, Melbourne, Australia
    Diabetes 57:2461-9. 2008
    ..This study examines the effects of deletion of RAGE on the development of atherosclerosis in the diabetic apoE(-/-) model of accelerated atherosclerosis...
  15. ncbi Large artery biomechanics and diastolic dysfunctionin patients with Type 2 diabetes
    G Soldatos
    Diabetes Complications Unit, Vascular Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    Diabet Med 28:54-60. 2011
    ..To comprehensively characterize large artery biomechanical properties and examine their relationship to cardiac function in patients with Type 2 diabetes mellitus (DM)...
  16. ncbi Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice
    Paul Lewis
    Oxidative Stress Group, JDRF Diabetes and Metabolism Division, Baker Heart Research Institute, PO Box 6492, St Kilda Rd Central, Melbourne, VIC 8008, Australia
    Circulation 115:2178-87. 2007
    ..We induced diabetes in mice deficient for both GPx1 and apolipoprotein E (ApoE) to determine whether this is merely an association or whether GPx1 has a direct effect on diabetes-associated atherosclerosis...
  17. ncbi Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice
    Markus Lassila
    Baker Heart Research Institute, P O Box 6492, Commercial Road, Melbourne 8008, VIC 3004, Australia
    J Am Soc Nephrol 16:363-73. 2005
    ..Tyrosine kinase inhibition with imatinib seems to retard the development of experimental diabetic nephropathy...
  18. ncbi Rapid potentiation of endothelium-dependent vasodilation by estradiol in postmenopausal women is mediated via cyclooxygenase 2
    A C Calkin
    Baker Medical Research Institute, St. Kilda Central, Melbourne 8008, Australia
    J Clin Endocrinol Metab 87:5072-5. 2002
    ..E had no effect on sodium nitroprusside-mediated vasodilation after any of the treatments. We conclude that the COX-2 pathway plays a specific role in the rapid E-induced potentiation of cholinergic vasodilation in postmenopausal women...
  19. ncbi Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux
    Anna C Calkin
    Diabetes Complications Laboratory, Baker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Rd Central, Melbourne, Australia 8008
    Circulation 120:2095-104. 2009
    ..Reconstituted high-density lipoprotein (rHDL) has short-term beneficial effects on atherosclerotic plaques, but whether it can effectively reduce the reactivity of diabetic platelets is not known...
  20. ncbi The clot thickens--oxidized lipids and thrombosis
    Shaun P Jackson
    Nat Med 13:1015-6. 2007